Print this page
-
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Protocol: 042314Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
The Women's Circle of Health Study.
Protocol: 130404Principal Investigator:
- Elisa Bandera M.D., Ph.D. (Rutgers University)
Applicable Disease Sites: Breast - Female -
INFORM Extended
Protocol: 042101Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Breast -
Adapting and Implementing Evidence-Based Breast Cancer Follow-up in Primary Care.
Protocol: 132103Principal Investigator:
- Shawna Hudson Ph.D. (Rutgers University)
Applicable Disease Sites: Breast -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Pancreas
Melanoma, Skin
Colon
Ovary
Soft Tissue
Prostate
Kidney
Breast